Goserelin 3.6 mg implant + Placebo

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 16/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Postpartum Depression

Conditions

Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis, Menopause, Neurodegeneration, Schizophrenia

Trial Timeline

Jan 1, 2011 → Dec 1, 2012

NCT ID

NCT02661789

About Goserelin 3.6 mg implant + Placebo

Goserelin 3.6 mg implant + Placebo is a pre-clinical stage product being developed by Brain Biotech for Postpartum Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT02661789. Target conditions include Postpartum Depression, Major Depressive Disorder, Postpartum Psychosis.

What happened to similar drugs?

3 of 10 similar drugs in Postpartum Depression were approved

Approved (3) Terminated (0) Active (7)

✅Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved

✅Eptacog alfa (NovoSeven)Novo NordiskApproved

✅ZULRESSO®Supernus PharmaceuticalsApproved

🔄Misoprostol + OxytocinCiplaPhase 3

🔄aripiprazoleBristol Myers SquibbPhase 3

🔄SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3

🔄SAGE-217 + PlaceboBiogenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02661789	Pre-clinical	Completed	Jan 1, 2011	Dec 1, 2012	Postpartum Depression

Competing Products

20 competing products in Postpartum Depression

See all competitors

Product	Company	Stage	Hype Score
Misoprostol + Oxytocin	Cipla	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	27
Azithromycin + Azithromycin and amoxicillin + Placebo	Merck	Approved	43
Eptacog alfa (NovoSeven)	Novo Nordisk	Approved	50
Eptacog alfa (activated)	Novo Nordisk	Pre-clinical	26
aripiprazole	Bristol Myers Squibb	Phase 3	40
fibrinogen concentrate + Placebo	CSL	Phase 1/2	24
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg Capsules	Biogen	Phase 3	37
SAGE-217 + Placebo	Biogen	Phase 3	37
Zuranolone	Biogen	Pre-clinical	30
Zuranolone	Biogen	Pre-clinical	30
LPCN 1154A + Placebo	Lipocine	Phase 3	30
ZULRESSO (brexanolone) injection	Supernus Pharmaceuticals	Pre-clinical	20
Placebo + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
ZULRESSO®	Supernus Pharmaceuticals	Approved	37
SAGE-547	Supernus Pharmaceuticals	Phase 2	29
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/h	Supernus Pharmaceuticals	Phase 3	34
SAGE-547 + Placebo	Supernus Pharmaceuticals	Phase 2	29
GH001	GH Research	Phase 2	21
Brexanolone	Brain Biotech	Pre-clinical	16